Al-Terki Abdulmohsen, Abu-Farha Mohamed, AlKhairi Irina, Cherian Preethi T, Sriraman Devarajan, Shyamsundar Ambika, Ali Shamsha, Almulla Fahd, Tuomilehto Jaakko, Abubaker Jehad A
Otolaryngology, Head & Neck Surgery, Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait.
Biochemistry and Molecular Biology Unit, Dasman Diabetes Institute, Kuwait City, Kuwait.
Front Endocrinol (Lausanne). 2018 Nov 13;9:651. doi: 10.3389/fendo.2018.00651. eCollection 2018.
Obstructive sleep apnea (OSA) is a sleep disorder caused by the complete or partial obstruction of the upper airways. The worldwide prevalence of OSA is increasing due to its close association with obesity epidemic and multiple health complications, such as hypertension, cardiovascular disease, and Type 2 diabetes. Angiopoietin-like protein (ANGPTL)-4 and ANGPTL8 (betatrophin) have been suggested to play a role in the development of these diseases through their role in regulating the metabolism of plasma lipid molecules. This study was designed to evaluate ANGPTL4 and 8 levels in an OSA group and a control group to clarify the effect of OSA on ANGPTL4 and 8 levels. In total, 74 subjects were enrolled in this study, including 22 age- and body mass index (BMI)-matched controls with the Apnea Hypopnea Index (AHI) score of <5 events/h and 52 subjects with an AHI score of >5 events/h. Sleep apnea was assessed using a portable sleep test. ANGPTL4 and 8 levels were measured in plasma samples using enzyme-linked immunosorbent assay. Mean AHI score (2.5 ± 1.6) in the control group was significantly lower than that in the OSA group (22.9 ± 17.9; < 0.0001). Leptin, interleukin-(IL) 6, insulin, and HOMA-IR values were higher in the OSA group than in the control group. ANGPTL8 level was higher in the OSA group (1130.0 ± 108.61 pg/mL) than in the control group (809.39 ± 108.78 pg/mL; = 0.041). Similarly, ANGPTL4 was higher in the OSA group (179.26 ± 12.89 ng/mL) than in the control group (142.63 ±7.99 ng/mL; = 0.018). Our findings demonstrate that ANGPTL4 and 8 levels were increased in subjects with OSA, suggesting that the upregulation of these lipid metabolism regulators might play a role in lipid dysregulation observed in people with OSA.
阻塞性睡眠呼吸暂停(OSA)是一种由上呼吸道完全或部分阻塞引起的睡眠障碍。由于其与肥胖流行以及多种健康并发症(如高血压、心血管疾病和2型糖尿病)密切相关,OSA在全球的患病率正在上升。血管生成素样蛋白(ANGPTL)-4和ANGPTL8(β-促胰岛素分泌素)已被认为通过调节血浆脂质分子代谢在这些疾病的发展中发挥作用。本研究旨在评估OSA组和对照组中ANGPTL4和8的水平,以阐明OSA对ANGPTL4和8水平的影响。本研究共纳入74名受试者,包括22名年龄和体重指数(BMI)匹配的对照组,其呼吸暂停低通气指数(AHI)得分<5次/小时,以及52名AHI得分>5次/小时的受试者。使用便携式睡眠测试评估睡眠呼吸暂停。使用酶联免疫吸附测定法测量血浆样本中ANGPTL4和8的水平。对照组的平均AHI得分(2.5±1.6)显著低于OSA组(22.9±17.9;<0.0001)。OSA组的瘦素水平、白细胞介素(IL)-6、胰岛素和HOMA-IR值高于对照组。OSA组的ANGPTL8水平(1130.0±108.61 pg/mL)高于对照组(809.39±108.78 pg/mL;P = 0.041)。同样,OSA组的ANGPTL4水平(179.26±12.89 ng/mL)高于对照组(142.63±7.99 ng/mL;P = 0.018)。我们的研究结果表明,OSA患者的ANGPTL4和8水平升高,表明这些脂质代谢调节因子的上调可能在OSA患者中观察到的脂质失调中起作用。